US equities |
NVDA $238.52 ▲+1.95% SPCX $167.14 ▲+5.15% MU $1,063.11 ▼-1.10% TSLA $380.50 ▲+2.67% MSFT $525.54 ▲+1.55% SNDK $1,709.19 ▼-0.63% INTC $117.11 ▼-1.86% META $743.37 ▲+2.10%
FinancialContent

Articles published by Lantern Pharma

News headline image
Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024
From Lantern Pharma
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort
From Lantern Pharma
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
From Lantern Pharma
Via Business Wire
Tickers LTRN
News headline image
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
From Lantern Pharma
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma
From Lantern Pharma
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University
From Lantern Pharma
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.
From Lantern Pharma
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021
From Lantern Pharma
Via AccessWire
Topics Artificial Intelligence
Tickers LTRN